News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
607,733 Results
Type
Article (46870)
Company Profile (193)
Press Release (560670)
Multimedia
Podcasts (105)
Webinars (13)
Section
Business (172473)
Career Advice (2530)
Deals (31837)
Drug Delivery (124)
Drug Development (76190)
Employer Resources (159)
FDA (16230)
Job Trends (13279)
News (305173)
Policy (31869)
Tag
Academia (2374)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (83)
Alliances (43340)
ALS (91)
Alzheimer's disease (1458)
Antibody-drug conjugate (ADC) (141)
Approvals (16194)
Artificial intelligence (265)
Autoimmune disease (27)
Automation (12)
Bankruptcy (324)
Best Places to Work (9920)
BIOSECURE Act (22)
Biosimilars (118)
Biotechnology (99)
Bladder cancer (81)
Brain cancer (29)
Breast cancer (274)
Cancer (2210)
Cardiovascular disease (186)
Career advice (2119)
Career pathing (34)
CAR-T (148)
Cell therapy (429)
Cervical cancer (19)
Clinical research (62053)
Collaboration (787)
Compensation (535)
Complete response letters (29)
COVID-19 (2652)
CRISPR (43)
C-suite (235)
Cystic fibrosis (95)
Data (2077)
Decentralized trials (2)
Denatured (24)
Depression (52)
Diabetes (276)
Diagnostics (5555)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (42)
Drug discovery (116)
Drug pricing (124)
Drug shortages (32)
Duchenne muscular dystrophy (97)
Earnings (69049)
Editorial (44)
Employer branding (20)
Employer resources (142)
Events (91994)
Executive appointments (696)
FDA (17476)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (673)
Gene editing (105)
Generative AI (23)
Gene therapy (320)
GLP-1 (813)
Government (3988)
Grass and pollen (6)
Guidances (55)
Healthcare (15497)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (140)
Indications (28)
Infectious disease (2801)
Inflammatory bowel disease (135)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (93)
Interviews (464)
IPO (15084)
IRA (49)
Job creations (3760)
Job search strategy (1768)
Kidney cancer (11)
Labor market (33)
Layoffs (519)
Leadership (24)
Legal (7717)
Liver cancer (75)
Lung cancer (317)
Lymphoma (153)
Machine learning (7)
Management (54)
Manufacturing (316)
MASH (72)
Medical device (11458)
Medtech (11462)
Mergers & acquisitions (17293)
Metabolic disorders (753)
Multiple sclerosis (77)
NASH (23)
Neurodegenerative disease (104)
Neuropsychiatric disorders (34)
Neuroscience (2016)
NextGen: Class of 2025 (5279)
Non-profit (3325)
Now hiring (22)
Obesity (415)
Opinion (243)
Ovarian cancer (68)
Pain (90)
Pancreatic cancer (79)
Parkinson's disease (155)
Partnered (18)
Patents (237)
Patient recruitment (103)
Peanut (45)
People (51125)
Pharmaceutical (81)
Pharmacy benefit managers (21)
Phase I (18640)
Phase II (27004)
Phase III (21443)
Pipeline (1196)
Policy (168)
Postmarket research (2551)
Preclinical (7729)
Press Release (48)
Prostate cancer (110)
Psychedelics (36)
Radiopharmaceuticals (232)
Rare diseases (403)
Real estate (5211)
Recruiting (64)
Regulatory (22367)
Reports (33)
Research institute (2189)
Resumes & cover letters (416)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (79)
Series A (126)
Series B (79)
Service/supplier (10)
Sickle cell disease (56)
Special edition (16)
Spinal muscular atrophy (150)
Sponsored (33)
Startups (3244)
State (2)
Stomach cancer (16)
Supply chain (73)
Tariffs (45)
The Weekly (79)
Vaccines (773)
Venture capitalists (43)
Weight loss (300)
Women's health (33)
Worklife (20)
Date
Today (169)
Last 7 days (851)
Last 30 days (2573)
Last 365 days (31448)
2025 (10421)
2024 (33287)
2023 (37222)
2022 (47704)
2021 (51385)
2020 (48650)
2019 (39201)
2018 (29904)
2017 (30548)
2016 (29175)
2015 (32677)
2014 (26562)
2013 (22192)
2012 (23752)
2011 (24429)
2010 (22346)
Location
Africa (761)
Alabama (43)
Alaska (7)
Arizona (186)
Arkansas (11)
Asia (37342)
Australia (6114)
California (5761)
Canada (1724)
China (482)
Colorado (257)
Connecticut (283)
Delaware (149)
Europe (85376)
Florida (874)
Georgia (184)
Hawaii (1)
Idaho (39)
Illinois (475)
India (27)
Indiana (263)
Iowa (11)
Japan (156)
Kansas (90)
Kentucky (21)
Louisiana (7)
Maine (62)
Maryland (863)
Massachusetts (4387)
Michigan (186)
Minnesota (332)
Mississippi (1)
Missouri (70)
Montana (17)
Nebraska (22)
Nevada (56)
New Hampshire (54)
New Jersey (1655)
New Mexico (16)
New York (1606)
North Carolina (957)
North Dakota (6)
Northern California (2540)
Ohio (166)
Oklahoma (10)
Oregon (31)
Pennsylvania (1258)
Puerto Rico (9)
Rhode Island (22)
South America (1136)
South Carolina (20)
South Dakota (1)
Southern California (2173)
Tennessee (91)
Texas (821)
United States (21613)
Utah (152)
Virginia (139)
Washington D.C. (61)
Washington State (522)
West Virginia (3)
Wisconsin (57)
607,733 Results for "veloxis pharmaceuticals a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Veloxis Pharmaceuticals Receives Approval from USAN for “Pegrizeprument” as Nonproprietary Name for VEL-101
February 26, 2025
·
3 min read
Bio NC
Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia
Veloxis Pharmaceuticals, Inc. is pleased to announce the presentation of VEL-101 research at the 2024 American Transplant Congress (ATC).
May 30, 2024
·
5 min read
Tariffs
Trump’s Tariffs Could Challenge Pharma’s Recession-Resistant Reputation
Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as GLP-1s dominate and the population grows older.
April 8, 2025
·
5 min read
·
Annalee Armstrong
Earnings
Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’
Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the pharmaceutical industry tariffs, which Trump has threatened, in part as a way to shore up U.S. national security.
April 29, 2025
·
3 min read
·
Annalee Armstrong
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
April 9, 2025
·
5 min read
Press Releases
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s
March 19, 2025
·
3 min read
Bio NC
Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 “Transforming Organ Transplantation Through Innovation” Challenge.
September 19, 2022
·
4 min read
Podcast
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
April 16, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
May 1, 2025
·
9 min read
1 of 60,774
Next
